Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|October 29, 2025
Patient preferences for EGFR mutation-targeted therapies in non-small cell lung cancer, with a focus on Exon 20 insertionsJaein Seo, Eileen Curran, Jennifer A Whitty, et al.JTO Clinical and Research Reports|August 18, 2025
Role of Quality of Life in Daily Functioning, Communication with Care Teams, and Treatment Decisions in Patients with ALK+ NSCLCHeather Law, Huamao M Lin, Eileen Curran, et al.The Oncologist|July 5, 2022
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United StatesMohammad Jahanzeb, Huamao M Lin, Yanyu Wu, et al.Future Oncology (London, England)|May 24, 2022
Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancerKaren L Reckamp, Huamao M Lin, Holly Cranmer, et al.Clinical Lung Cancer|December 19, 2023
Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment ComparisonSai-Hong Ignatius Ou, Thibaud Prawitz, Huamao M Lin, et al.Journal of Clinical Medicine|January 8, 2023
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension CohortMaria Rosario Garcia Campelo, Caicun Zhou, Suresh S Ramalingam, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 13, 2023
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 TrialJames Chih-Hsin Yang, Geoffrey Liu, Shun Lu, et al.Lung Cancer (Amsterdam, Netherlands)|April 14, 2023
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutationsPetros Christopoulos, Thibaud Prawitz, Jin-Liern Hong, et al.JAMA Oncology|October 14, 2021
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical TrialCaicun Zhou, Suresh S Ramalingam, Tae Min Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2025
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialPasi A Jänne, Bin-Chao Wang, Byoung Chul Cho, et al.Pageof 4